表达IL7和CCL19并联合PD-1单抗的第四代CD19 CAR-T治疗复发或难治性大B细胞淋巴瘤的疗效与安全性
本研究在本中心应用自体7×19 CAR-T联合替雷利珠单抗治疗11例复发或难治性大B细胞淋巴瘤患者,评估疗效及不良反应。5例(45.5%)达完全缓解,3例(27.3%)达部分缓解,客观缓解率72.7%,最佳完全缓解率63.6%;细胞因子释放综合征和免疫效应细胞相关神经毒性综合征均可控,未见免疫相关不良反应。
要点
- 11例复发或难治性大B细胞淋巴瘤患者接受自体7×19 CAR-T联合替雷利珠单抗治疗。
- 客观缓解率72.7%,最佳完全缓解率63.6%,中位无进展生存28(1~34)个月。
- 细胞因子释放综合征和免疫效应细胞相关神经毒性综合征均可控,未见免疫相关不良反应。
核心结论
- 自体7×19 CAR-T联合替雷利珠单抗治疗复发或难治性大B细胞淋巴瘤取得较好疗效,且不良反应可控。
研究设计与样本
- 本中心应用自体7×19 CAR-T联合替雷利珠单抗治疗11例复发或难治性大B细胞淋巴瘤患者,评估疗效及不良反应。
主要发现
- 11例入组患者均完成自体7×19 CAR-T的制备和回输,9例完成预定的6次替雷利珠单抗治疗,1例完成4次,1例完成1次。
- 5例(45.5%)达完全缓解,3例(27.3%)达部分缓解,客观缓解率72.7%;2例评估为疾病进展,1例在回输后2个月因疾病不能控制而死亡。
- 中位随访时间31(2~34)个月,中位总生存时间未达到,中位无进展生存时间为28(1~34)个月。
- 2例部分缓解患者分别在随访第9个月和第12个月进一步获得完全缓解,最佳完全缓解率为63.6%。
- 细胞因子释放综合征和免疫效应细胞相关神经毒性综合征均可控,未见免疫相关不良反应发生。
临床怎么用
- 本研究中心的做法是应用自体7×19 CAR-T联合替雷利珠单抗治疗复发或难治性大B细胞淋巴瘤患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: This study systematically explore the efficacy and safety of fourth-generation chimeric antigen receptor T-cells (CAR-T), which express interleukin 7 (IL7) and chemokine C-C motif ligand 19 (CCL19) and target CD19, in relapsed or refractory large B-cell lymphoma. Methods: Our center applied autologous 7×19 CAR-T combined with tirelizumab to treat 11 patients with relapsed or refractory large B-cell lymphoma. The efficacy and adverse effects were explored. Results: All 11 enrolled patients completed autologous 7×19 CAR-T preparation and infusion. Nine patients completed the scheduled six sessions of tirolizumab treatment, one completed four sessions, and one completed one session. Furthermore, five cases (45.5%) achieved complete remission, and three cases (27.3%) achieved partial remission with an objective remission rate of 72.7%. Two cases were evaluated for disease progression, and one died two months after reinfusion because of uncontrollable disease. The median follow-up time was 31 (2-34) months, with a median overall survival not achieved and a median progression-free survival of 28 (1-34) months. Two patients with partial remission achieved complete remission at the 9th and 12th months of follow-up. Therefore, the best complete remission rate was 63.6%. Cytokine-release syndrome and immune effector cell-associated neurotoxicity syndrome were controllable, and no immune-related adverse reactions occurred. Conclusion: Autologous 7×19 CAR-T combined with tirelizumab for treating relapsed or refractory large B-cell lymphoma achieved good efficacy with controllable adverse reactions. 目的: 系统性研究表达白细胞介素7(IL7)和趋化因子C-C基序配体19(CCL19)的第四代靶向CD19嵌合抗原受体T细胞(CD19 CAR-T)联合PD-1单抗治疗复发难治大B细胞淋巴瘤的疗效及安全性。 方法: 应用自体7×19 CAR-T联合替雷利珠单抗治疗11例复发难治大B细胞淋巴瘤患者,评估其疗效及不良反应。 结果: 11例入组患者均完成自体7×19 CAR-T的制备和回输,9例患者完成预定的6次替雷利珠单抗治疗,1例患者完成4次,1例患者完成1次。5例(45.5%)达完全缓解,3例(27.3%)达部分缓解,客观缓解率72.7%。2例评估为疾病进展,1例在回输后2个月因疾病不能控制而死亡。中位随访时间31(2~34)个月,中位总生存时间未达到,中位无进展生存时间为28(1~34)个月,2例部分缓解患者分别在随访第9个月和第12个月进一步获得完全缓解,故最佳完全缓解率为63.6%。细胞因子释放综合征和免疫效应细胞相关神经毒性综合征均可控,未见免疫相关不良反应发生。 结论: 自体7×19 CAR-T联合替雷利珠单抗治疗复发难治大B细胞淋巴瘤取得较好疗效,且不良反应可控。.
引用
- Yu T, Liu H, Lei W, et al. [Efficacy and safety of fourth-generation CD19 CAR-T expressing IL7 and CCL19 along with PD-1 monoclonal antibody for relapsed or refractory large B-cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2023. PMID: 38049333. doi:10.3760/cma.j.issn.0253-2727.2023.10.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。